Eosinophils, ribonucleases and host defense: Solving the puzzle

Immunologic Research

Volumn 20, Issue 2, 1999, Pages 261-274

  Rosenberg, Helene F ^a   Domachowske, Joseph B ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Antiviral agents; Eosinophilis; Host defense; Ribonucleases

Indexed keywords

ANTIVIRUS AGENT; EOSINOPHIL CATIONIC PROTEIN; NEUROTOXIN; RIBONUCLEASE; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; EOSINOPHIL; EVOLUTION; HOST RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTIVITY;

EID: 0033507441     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02790409     Document Type: Review

References (66)

1. 1 Ehrlich P: On the specific granulations of blood [translation]. Arch Anat Physiol 1897;166.
2. 2 Rosenberg HF: Eosinophils; in Gallin JI, Snyderman R (eds): Inflammation: basic research and clinical correlates. Philadelphia, PA, Lippincott Williams & Wilkins, 1999, pp. 61-76.
3. 3 Sher A, Coffman RL, Hieny S, Cheever AW. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 1990;145:3911-3916.
4. 4 Herndon FJ, Kayes SG. Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. J Immunol 1992;149:3642-3647.
5. 5 Freeman GL, Tominaga A, Takatsu K, Secor WE, Colley DG. Elevated innate peripheral blood eosinophilia fails to augment irradiated cercarial vaccine-induced resistance to Schistosoma mansoni in IL-5 transgenic mice. J Parasitol 1995;81:1010-1011.
6. 6 Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA Kohler G, Young IG, Matthaei KI. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996; 4:15-24.
7. 7 Korenaga M, Hitoshi Y, Yamaguchi N, Sato Y, Takatsu K, Tada I. The role of interleukin-5 in protective immunity to Strongyloides venezuelensis infection in mice. Immunology 1991;72:502-507.
8. 8 Folkard SG, Hogarth PJ, Taylor MJ, Bianco AE: Eosinophils are the major effector cells of immunity to microfilariae in a mouse model of onchocerciasis. Parasitology 1996;112:323-329.
9. 9 Nutten S, Papin JP, Woerly G, Dunne DW, MacGregor J, Trottein F, Capron M. Selectin and Lewis-X are required as co-receptors in antibody-dependent cell-mediated cytotoxicity of human eosinophils to Schistosoma mansoni schistosomula. Eur J Immunol 1999;29:799-808.
10. 10 Betts CJ, Else KJ: Mast cells, eosinophils and antibody-mediated cellular cytotoxicity are not critical in resistance to Trichuris muris. Parasite Immunol 1999;21:45-52.
11. 11 Wong DTW, Weller PF, Galli SJ, et al: Human eosinophils express transforming growth factor alpha. J Exp Med 1990;172:673-681.
12. 12 Todd R, Donoff BR, Chiang T, et al: The eosinophil as a cellular source of tranforming growth factor alpha in healing cutaneous wounds. Am J Pathol 1991;138: 1307-1313.
13. 13 Lucey DR, Nicholson-Weller A, Weller PF: Mature human eosinophils have the capacity to express HLA-DR. Proc Natl Acad Sci USA 1989;86:1348-1351.
14. 14 Hansel TT, deVries IJ, Carballido JM, Braun RK, Carballido-Perrig N, Rihs S, Blaser K, Walker C. Induction and function of eosinophil intercellular adhesion molecule 1 and HLA-DR. J Immunol 1992;149:2130-2136.
15. 15 Del Pozo V, De Andres B, Martin E, Cardaba B, Fernandez JC, Gallardo S, Tramon P, Leyva-Cobain F, Palomino P, Lahoz C: Eosinophil as antigen-presenting cell: activation of T cell clones and T cell hybridoma by eosinophils after antigen processing. Eur J Immunol 1992;22:1919-1925.
16. 16 Mawhorter SD, Kazura JW, Boom WH: Human eosinophils as anti-gen presenting cells: relative efficiency for superantigen and antigen induced CD4+ T-cell proliferation. Immunology 1994;81:584-591.
17. 17 Archer GT, Hirsch JB. Isolation of granules from eosinophil leucocytes and study of their enzyme content. J Exp Med 1963;118:277-284.
18. 18 Olsson I, Venge P, Sptiznagel JK, Lehrer RI: Arginine-rich cationic proteins of human eosinophil granules. Comparison of the constitutents of eosinophilic and neutrophilic leukocytes. Lab Invest 1977;36: 493-500.
19. 19 Olsson I, Persson AM, Winqvist I: Biochemical properties of eosinophil cationic protein and demonstration of its biosynthesis in vitro in marrow cells from patients with eosinophilia. Blood 1986;67: 498-503.
20. 20 Durack DT, Sumi SM, Klebanoff SJ: Neurotoxicity of human eosinophils. Proc Natl Acad. Sci USA 1979;76:1443-1447.
21. 21 Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci USA 1981;78:5165-5169.
22. 22 Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ: Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 1986;83: 3146-3150.
23. 23 Rosenberg HF, Tenen DG, Ackerman SJ: Molecular cloning of the human eosinophil-derived neurotoxin: a member of the ribonuclease gene family. Proc Natl Acad Sci USA 1989;86:4460-4464.
24. 24 Hamann KJ, Barker RL, Loegering DA, Pease LR, Gleich GJ: Sequence of human eosinophil-derived neurotoxin cDNA: identity of deduced amino acid sequence with human non-secretory ribonucleases. Gene 1989;83:161-167.
25. 25 Rosenberg HF, Ackerman SJ, Tenen DG. Human eosinophil cationic protein: molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 1989;170:163-176.
26. 26 Barker RL, Loegering DA, Ten RM, Hamann KJ, Pease LR, Gleich GJ: Eosinophil cationic protein cDNA: comparison with other toxic cationic proteins and ribonucleases. J Immunol 1989;143: 952-955.
27. 27 Slifman NR, Loegering DA, McKean DJ, Gleich GJ: Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 1986;137: 2913-2917.
28. 28 Gullberg U, Widegren B, Arivason U, Egesten A, Olsson I: The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. Biochem Biophys Res Commun 1986;139:1239-1242.
29. 29 Rosenberg HF: The eosinophil ribonucleases. Cell Mol Life Sci 1998;54:795-803.
30. 30 Newton DK, Walbridge S, Mikulski SM, Ardelt W, Shogen K, Ackerman SJ, et al: Toxicity of an anti-tumor ribonuclease to Purkinje neurons. J Neuroxic 1994;14: 538-544.
31. 31 Sorentino S, Glitz, DG, Hamann KJ, Loegering DA, Checkel JL, Gleich GJ: Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. J Biol Chem 1992;267: 14589-14565.
32. 32 Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: biology and role in disease. Adv Immunol 1995;60:1 51-266.
33. 33 Silberstein DS: Eosinophil function in health and disease. Crit Rev Oncol Hematol 1995;19:47-77.
34. 34 Young JDE, Peterson CGB, Venge P, Cohn ZA: Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986;321:613-616.
35. 35 Rosenberg HF: Recombinant eosinophil cationic protein (ECP): ribonuclease activity is not essential for cytotoxicity. J Biol Chem 1995;270:7876-7881.
36. 36 Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ: Toxic effects produced or mediated by human eosinphil granule components on Trypanosoma cruzi. Am J Trop Med Hyg 1988;38:327-334.
37. 37 Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M: Rapid evolution of a unique family of primate ribonuclease genes. Nature Genetics 1995;10:219-223.
38. 38 Murphy PM: Molecular mimicry and the generation of host defense protein diversity. Cell 1993;72: 823-826.
39. 39 Zhang J, Rosenberg HF, Nei M: Positive Darwinian selection after gene duplication in primate ribonuclease genes. Proc Natl Acad Sci USA 1998;95:3708-3713.
40. 40 Rosenberg HF, Dyer DK: Eosinophil cationic protein and eosinophil-derived neurotoxin: evolution of novel function in a primate ribonuclease gene family. J Biol Chem 1995;270:21,539-21,544.
41. 41 Rosenberg HF, Dyer KD: Diversity among the primate eosinophil-derived neurotoxin genes: a specific carboxy-terminal sequence is necessary for enhanced ribonuclease activity. Nucleic Acids Res 1997;35:3532-3536.
42. 42 Rosenberg HF, Dyer KD: Molecular cloning and characterization of a novel human ribonuclease (RNase k6): increasing diversity in the enlarging ribonuclease gene family. Nucleic Acids Res 1996;24:3507-3513.
43. 43 Deming MS, Dyer KD, Bankier AT, Piper MB, Dear PH, Rosenberg HF: Ribonuclease k6: chromosomal localization and divergen rates of evolution in the RNase A superfamily. Genome Res 1998;8: 599-607.
44. 44 Larson KA, Olson EA, Maden BJ, Gleich GJ, Lee NA, Lee JJ: Two highyly homologous ribonuclease genes expressed in mouse eoisnophils identify a larger subgroup of the mammalian ribonuclease superfamily. Proc Natl Acad Sci USA 1996;93:12,370-12,375.
45. 45 Batten D, Dyer KD, Domachowske JB, Rosenberg HF: Molecular cloning of four novel murine ribonuclease genes: unusual expansion within the Ribonuclease A gene family. Nucleic Acids Res 1997;25:4235-4239.
46. 46 Singhania NA, Dyer KD, Zhang J, Deming MS, Bonville CA, Domachowske JB, Rosenberg HF: Rapid evolution of the RNase A superfamily: adaptive expansion of inde-pendent gene clusters in rats and mice. J Mol Evol 1999;49:721-728.
47. 47 Collins PL, McIntosh K, Chanock RM: Respiratory syncytial virus, Fields BN, Knipe DM, Howley PM, eds. Fields Virology, 2nd ed. Lippincott-Raven Publishers, Philadelpha PA; 1996; pp. 1313-1351.
48. 48 Prober CG, Wang EEL: Reducing the morbidity of lower respiratory tract infectious caused by respiratory syncytial virus: still no answer. Pediatrics 1997;99:472-475.
49. 49 Domachowske JB, Rosenberg HF: Respiratory syncytial virus infection: immune response, immunopathogenesis and treatment. Clin Microbiol Rev 1999;12:298-309.
50. 50 Garofalo R, Kimpen JLL, Welliver RC, Ogra PL: Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatrics 1992;120:28-32.
51. 51 Kimpen JL, Garofalo R, Welliver RC, Ogra PL: Activation of human eosinophils by respiratory syncytial virus. Pediatric Res 1992;32: 160-164.
52. 52 Arnold RB, Humbert H, Werchau H, Gallati H, Konig W: Interleukin-8, interleukin-6 and soluble tumor necrosis factor receptor type-1 release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 1994;8:20-27.
53. 53 Fiedler MA, Wernke-Dollries K, Stark JM: Respiratory syncytial virus increases IL-8 gene expression and protein release in A549 cells. Am J Phyisol 1995;269: L865-L872.
54. 54 Becker S, Reed W, Henderson RW, Noah TL: RSV infection of airway epithelial cells causes production of the beta-chemokine RANTES. Am J Physiol 1997; 272:L512-L520.
55. 55 Saito T, Deskin RW, Casola A, Haeberle H, Olszewska B, Ernst PB, Alam R, Ogra P, Garofalo R: Respiratory syncytial virus induced selective production of the chemokine RANTES by upper airway epithelial cells. J Infect Dis 1997;175:497-504.
56. 56 Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB: Respiratory syncytial virus infection induces expression of macrophage inflammatory protein 1-alpha (MIP-1-alpha) in the human lower respiratory tract in vivo: association with eosinophil recruitment and degranulation. Am J Resp Dis Crit Care Med 1999;159:1918-1924.
57. 57 Stark JM, Godding V, Sedgewick JB, Busse WW: Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. J Immunol 1996; 156: 4774-4782.
58. 58 Schwarze J, Cieslewicz G, Hamelmann E, Joetham A, Schultz LD, Lamers MC, Gelfand EW: IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection. J Immunol 1999;162:2997-3004.
59. 59 Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Hamelmann E, Gelfand EW: CD8 T cells are essential in the development of respiratory syncytial virus-induced lung eosinophilia and airway hyperresponsiveness. J Immunol 1999;162:4207-4211.
60. 60 Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF: Recombinant human eosinophil-derived neurotoxin / RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998; 177:1458-1464.
61. 61 Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF: Eosinophil cationic protein (ECP / RNase 3): another eosinophil ribonuclease with direct antiviral activity. Nucleic Acids Res 1998;26:3358-3363.
62. 62 Domachowske JB, Bonville CA, Dyer KD, Rosenberg HF: Evolution of antiviral activity in the Ribonuclease A gene superfamily: evidence for a specific interaction between eosinophil-derived neurotoxin (EDN / RNase 2) and respiratory syncytial virus. Nucleic Acids Res 1998;26:5327-5332.
63. 63 Motojima S, Frigas E, Loegering DA, Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pic tracheal epithelia in vitro. Am Rev Respir Dis 1989;139: 801-805.
64. 64 Vasandani VM, Wu YN, Mikulski SM, Youle RJ, Sung C: Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily. Cancer Res 1996; 56:4180-4186.
65. 65 Kimura M: A simple method for estimating evolutionary rate of base substitution through comparative studies of nucleotide sequences. J Mol Evol 1980;16: 111-120.
66. 66 Kumar S, Tamura K, Nei M: Molecular Evolutionary Genetics Analysis, version 1.02, Institute of Molecular Evolutionary Genetics, The Pennsylvania State University, PA.